~~<i id='B7E24BFE6B'><strike id='B7E24BFE6B'><tt id='B7E24BFE6B'><pre id='B7E24BFE6B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

author：hotspot 2025-09-29 18:17:10 - browse：84575

Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Medicare explains how it will choose drugs for negotiation

leisure time

hotspot

Wikipedia

focus

leisure time

knowledge

AdobeAdvancementsinLLMssuchasChatGPTandGPT-4havegeneratedsubstantialexcitement.Manyseethesemodelsasa

WSS

Departing Stanford president retracts two papers

Why more medical students aren't specializing in primary care

California man arrested in connection with serial murders of Mexican strip club workers

Neuroscience startup Neumora files for IPO

Study finds new variant for Parkinson’s in African populations

Neuroscience startup Neumora files for IPO

leisure time

leisure time

leisure time

As demand for Covid shots wanes, Moderna seeks its next success

Titanic submersible: What a 'catastrophic implosion' means and what officials found

How to save PrEP access — and even expand it

Neuroscience startup Neumora files for IPO

Novavax promises a turnaround & Lilly roils the obesity market

CDC advisory panel says seniors 'may' get RSV vaccine

Continuity nursing helped my family in our darkest PICU moments

Sen. Bill Cassidy on how to lower drug prices

Affirmative action in medical school literally saved lives

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

hotspot

With fresh data, a dynamic duo powers Eli Lilly to new heights

Apellis safety probe of eye disease drug centers on injection needle

FDA approves Leqembi, a milestone in Alzheimer’s treatment

UPS workers' union leader explains what's at stake as strike edges closer

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

Diversity in medical illustrations gets boost from Chidiebere Ibe

Wikipedia

focus

leisure time

knowledge